Vaxcyte, Inc. (PCVX): R&D Expense
$794.31M
Year ended 2025-12-31
$1.03B
Trailing 12 months to 2026-06-30
+67.4%
3-year compound annual growth
+60.9%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $794.31M | +66.6% | 2026-02-24, From 2025-01-01 |
| 2024-12-31 | $476.64M | +43.4% | 2026-02-24, From 2024-01-01 |
| 2023-12-31 | $332.34M | +96.1% | 2026-02-24, From 2023-01-01 |
| 2022-12-31 | $169.45M | +116.1% | 2025-02-25, From 2022-01-01 |
| 2021-12-31 | $78.41M | +6.6% | 2024-02-27, From 2021-01-01 |
| 2020-12-31 | $73.56M | +61.3% | 2023-02-27, From 2020-01-01 |
| 2019-12-31 | $45.61M | +51.3% | 2022-02-28, From 2019-01-01 |
| 2018-12-31 | $30.14M | n/a | 2021-03-29, From 2018-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Vaxcyte, Inc. (PCVX) | 2025-12-31 | $794.31M | +66.6% |
| Repligen Corp (RGEN) | 2025-12-31 | $54.18M | +25.4% |
| Exelixis, Inc. (EXEL) | 2026-01-02 | $825.00M | -9.4% |
| Bio-Techne Corp (TECH) | 2026-06-30 | $94.77M | -4.8% |
| Halozyme Therapeutics, Inc. (HALO) | 2025-12-31 | $81.49M | +3.1% |
| Revolution Medicines, Inc. (RVMD) | 2025-12-31 | $987.33M | +66.7% |
| CRISPR Therapeutics AG (CRSP) | 2025-12-31 | $284.81M | -8.2% |
| Neurocrine Biosciences Inc (NBIX) | 2025-12-31 | $1.02B | +38.9% |
| Kymera Therapeutics, Inc. (KYMR) | 2025-12-31 | $316.57M | +31.8% |
Compare PCVX, RGEN, EXEL, TECH side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗